Vericel (VCEL) Cash & Equivalents (2010 - 2026)
Vericel recorded quarterly Cash & Equivalents of $109.3 million in Q1 2026, up 9.19% quarter-over-quarter from $100.1 million in Q4 2025, and up 48.72% year-over-year from $73.5 million in Q1 2025.
Vericel's Cash & Equivalents history runs 15 years deep, the most recent figure standing at $109.3 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 48.72% year-over-year to $109.3 million; the TTM figure through Mar 2026 stood at $109.3 million (up 48.72% YoY), while the FY2025 annual figure was $100.1 million, up 34.32% from the prior year.
- Cash & Equivalents came in at $109.3 million for Q1 2026 at Vericel, up from $100.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $109.3 million in Q1 2026 to a low of $43.0 million in Q2 2023.
- A 5-year average of $68.7 million and a median of $62.9 million in 2024 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents retreated 25.26% in 2022 and jumped 87.04% in 2025, its largest moves.
- Vericel's Cash & Equivalents stood at $51.1 million in 2022, then soared by 35.29% to $69.1 million in 2023, then advanced by 7.86% to $74.5 million in 2024, then surged by 34.32% to $100.1 million in 2025, then climbed by 9.19% to $109.3 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $109.3 million, $100.1 million, and $100.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | 109.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.30 Mn |
| Dec 31, 2025 | 100.09 Mn |
| Sep 30, 2025 | 100.40 Mn |
| Jun 30, 2025 | 80.53 Mn |
| Mar 31, 2025 | 73.49 Mn |
| Dec 31, 2024 | 74.52 Mn |
| Sep 30, 2024 | 53.68 Mn |
| Jun 30, 2024 | 50.29 Mn |
| Mar 31, 2024 | 62.94 Mn |
| Dec 31, 2023 | 69.09 Mn |
| Sep 30, 2023 | 60.47 Mn |
| Jun 30, 2023 | 43.02 Mn |
| Mar 31, 2023 | 61.83 Mn |
| Dec 31, 2022 | 51.07 Mn |
| Sep 30, 2022 | 65.22 Mn |
| Jun 30, 2022 | 56.05 Mn |
| Mar 31, 2022 | 55.66 Mn |
| Dec 31, 2021 | 68.33 Mn |
| Sep 30, 2021 | 54.55 Mn |
| Jun 30, 2021 | 51.76 Mn |
| Mar 31, 2021 | 58.15 Mn |
| Dec 31, 2020 | 33.62 Mn |
| Sep 30, 2020 | 43.51 Mn |
| Jun 30, 2020 | 55.70 Mn |
| Mar 31, 2020 | 45.62 Mn |
| Dec 31, 2019 | 26.89 Mn |
| Sep 30, 2019 | 36.90 Mn |
| Jun 30, 2019 | 14.00 Mn |
| Mar 31, 2019 | 35.08 Mn |
| Dec 31, 2018 | 18.29 Mn |
| Sep 30, 2018 | 53.29 Mn |
| Jun 30, 2018 | 94.97 Mn |
| Dec 31, 2017 | 26.86 Mn |
| Dec 31, 2014 | 30.34 Mn |
| Sep 30, 2014 | 37.58 Mn |
| Jun 30, 2014 | 7.30 Mn |
| Dec 31, 2013 | 8.06 Mn |
| Sep 30, 2013 | 10.82 Mn |
| Jun 30, 2013 | 4.49 Mn |
| Mar 31, 2013 | 9.23 Mn |
| Dec 31, 2012 | 13.64 Mn |
| Sep 30, 2012 | 21.09 Mn |
| Jun 30, 2012 | 28.67 Mn |
| Mar 31, 2012 | 36.73 Mn |
| Dec 31, 2011 | 5.53 Mn |
| Sep 30, 2011 | 11.95 Mn |
| Jun 30, 2011 | 18.52 Mn |
| Mar 31, 2011 | 24.62 Mn |
| Dec 31, 2010 | 31.25 Mn |
| Sep 30, 2010 | 14.47 Mn |
| Jun 30, 2010 | 14.12 Mn |